Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 5/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334602 | 0.81 | HTR2C (0.50) | HTR2CHTR2AHTR6CNR1CNR2 | |
| SCHEMBL29967860 | 0.80 | GRM2 (0.48) | HTR6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23648121 | 0.80 | GRM2 (0.48) | HTR6TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL31694729 | 0.80 | TUBB4A (0.41) | HTR2CHTR2AHTR6TUBB4ATUBB | |
| SCHEMBL19117682 | 0.78 | CNR1 (0.48) | HTR2CHTR2ACNR1CNR2 | |
| SCHEMBL4321418 | 0.77 | HTR2C (0.60) | HTR2CHTR2AHTR6 | |
| SCHEMBL29751560 | 0.75 | HTR2C (0.63) | HTR2CHTR2AHTR6 | |
| SCHEMBL4323537 | 0.75 | HTR2C (0.63) | HTR2CHTR2AHTR6 | |
| SCHEMBL3142772 | 0.75 | CNR1 (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3139209 | 0.74 | NR4A2 (0.49) | CNR1CNR2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| CN-100349887-C | Substituted 4-aryl-4H-pyrrolo [2, 3-H ] chromenes and analogs, pharmaceutical compositions and uses thereof | CYTOVIA INC (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1509515-A4 | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| CN-1668609-A | Substituted 4-aryl-4H-pyrrolo[2,3-H]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA INC (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1509515-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097806-A2 | SUBSTITUTED 4-ARYL-4H-PYRROLO[2,3-H]CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP2 | HTR2C 2142/4885HTR2A 1819/4885HTR6 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.